2026 Q2 - tulosraportti
58 päivää sitten
‧48 min
1,00 NOK/osake
Viimeisin osinko
30,12%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 995 | - | - | ||
| 5 184 | - | - | ||
| 4 816 | - | - | ||
| 500 | - | - | ||
| 819 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
4 t sittenNykode Therapeutics to Present Trial-in-Progress Poster Highlighting the Design of the Phase 2 Abili-T Trial of Lead Cancer Vaccine Abi-Suva at ESMO Congress 2026 https://newsweb.oslobors.no/message/684675
·4 t sittenModerna down 17.5% yesterday - was down over 25%. Don't follow this stock but some say the study design is a "problem".
I think sell-the-news, many had a lot of profit to take in Moderna. Perhaps amplified by stop-loss and panic. Since they are chosen to present on the stage they have been given (LBA1) it doesn't seem likely that there is a problem with study design
4 t sittenFra FT: A cancer vaccine being developed by Merck and Moderna significantly reduced melanoma deaths compared to conventional treatments, according to data released on Thursday, though an online leak of the study prompted chaotic trading in their shares. Although the results were in line with analysts’ expectations, Moderna’s shares sank about 18 per cent. The data was not scheduled to be published until Saturday but the companies released it after details of the trial results leaked out. The results follow an August announcement from Merck and Moderna that said messenger RNA technology (mRNA) combined with conventional melanoma treatments proved successful in stopping cancer from returning and spreading in patients whose melanomas had been removed. Moderna’s shares more than doubled after the announcement; the Boston-based biotech remains the best performer in the S&P 500 index this year despite Thursday’s drop. The latest trial results provided more information, specifically about the timing for a patient’s survival. After six months, the combination of mRNA and Merck’s cancer-killing drug Keytruda reduced the risk of tumour recurrence or death by 58 per cent, the companies said. The timing of patients’ recurrence-free survival was in line with analysts’ estimates but failed to significantly improve upon Wall Street’s expectations. The reduction in cancer recurrences and death is meaningful, said Evan Seigerman, analyst at BMO Capital Markets. The share price reaction “likely reflects inflated expectations into the full data release, rather than a true indictment of the efficacy of the combo therapy”, he said. “These results are not enough to drive confidence amidst elevated expectations,” he added. Merck’s shares on Thursday dropped after the leak but recovered and ended the day down 1 per cent. Moderna’s shares were down as much as 25 per cent in intraday trading. Analysts said it remains uncertain how the melanoma results can be applied to other cancers. Merck and Moderna are also testing their therapies in bladder, lung and other cancers. Thursday’s published results were a final phase 3 trial that has been in the works since 2023. The companies have said they are meeting the US drug regulator and expect approval next year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧48 min
1,00 NOK/osake
Viimeisin osinko
30,12%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenNykode Therapeutics to Present Trial-in-Progress Poster Highlighting the Design of the Phase 2 Abili-T Trial of Lead Cancer Vaccine Abi-Suva at ESMO Congress 2026 https://newsweb.oslobors.no/message/684675
- ·4 t sittenModerna down 17.5% yesterday - was down over 25%. Don't follow this stock but some say the study design is a "problem".I think sell-the-news, many had a lot of profit to take in Moderna. Perhaps amplified by stop-loss and panic. Since they are chosen to present on the stage they have been given (LBA1) it doesn't seem likely that there is a problem with study design
- 4 t sittenFra FT: A cancer vaccine being developed by Merck and Moderna significantly reduced melanoma deaths compared to conventional treatments, according to data released on Thursday, though an online leak of the study prompted chaotic trading in their shares. Although the results were in line with analysts’ expectations, Moderna’s shares sank about 18 per cent. The data was not scheduled to be published until Saturday but the companies released it after details of the trial results leaked out. The results follow an August announcement from Merck and Moderna that said messenger RNA technology (mRNA) combined with conventional melanoma treatments proved successful in stopping cancer from returning and spreading in patients whose melanomas had been removed. Moderna’s shares more than doubled after the announcement; the Boston-based biotech remains the best performer in the S&P 500 index this year despite Thursday’s drop. The latest trial results provided more information, specifically about the timing for a patient’s survival. After six months, the combination of mRNA and Merck’s cancer-killing drug Keytruda reduced the risk of tumour recurrence or death by 58 per cent, the companies said. The timing of patients’ recurrence-free survival was in line with analysts’ estimates but failed to significantly improve upon Wall Street’s expectations. The reduction in cancer recurrences and death is meaningful, said Evan Seigerman, analyst at BMO Capital Markets. The share price reaction “likely reflects inflated expectations into the full data release, rather than a true indictment of the efficacy of the combo therapy”, he said. “These results are not enough to drive confidence amidst elevated expectations,” he added. Merck’s shares on Thursday dropped after the leak but recovered and ended the day down 1 per cent. Moderna’s shares were down as much as 25 per cent in intraday trading. Analysts said it remains uncertain how the melanoma results can be applied to other cancers. Merck and Moderna are also testing their therapies in bladder, lung and other cancers. Thursday’s published results were a final phase 3 trial that has been in the works since 2023. The companies have said they are meeting the US drug regulator and expect approval next year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 995 | - | - | ||
| 5 184 | - | - | ||
| 4 816 | - | - | ||
| 500 | - | - | ||
| 819 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
1,00 NOK/osake
Viimeisin osinko
30,12%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenNykode Therapeutics to Present Trial-in-Progress Poster Highlighting the Design of the Phase 2 Abili-T Trial of Lead Cancer Vaccine Abi-Suva at ESMO Congress 2026 https://newsweb.oslobors.no/message/684675
- ·4 t sittenModerna down 17.5% yesterday - was down over 25%. Don't follow this stock but some say the study design is a "problem".I think sell-the-news, many had a lot of profit to take in Moderna. Perhaps amplified by stop-loss and panic. Since they are chosen to present on the stage they have been given (LBA1) it doesn't seem likely that there is a problem with study design
- 4 t sittenFra FT: A cancer vaccine being developed by Merck and Moderna significantly reduced melanoma deaths compared to conventional treatments, according to data released on Thursday, though an online leak of the study prompted chaotic trading in their shares. Although the results were in line with analysts’ expectations, Moderna’s shares sank about 18 per cent. The data was not scheduled to be published until Saturday but the companies released it after details of the trial results leaked out. The results follow an August announcement from Merck and Moderna that said messenger RNA technology (mRNA) combined with conventional melanoma treatments proved successful in stopping cancer from returning and spreading in patients whose melanomas had been removed. Moderna’s shares more than doubled after the announcement; the Boston-based biotech remains the best performer in the S&P 500 index this year despite Thursday’s drop. The latest trial results provided more information, specifically about the timing for a patient’s survival. After six months, the combination of mRNA and Merck’s cancer-killing drug Keytruda reduced the risk of tumour recurrence or death by 58 per cent, the companies said. The timing of patients’ recurrence-free survival was in line with analysts’ estimates but failed to significantly improve upon Wall Street’s expectations. The reduction in cancer recurrences and death is meaningful, said Evan Seigerman, analyst at BMO Capital Markets. The share price reaction “likely reflects inflated expectations into the full data release, rather than a true indictment of the efficacy of the combo therapy”, he said. “These results are not enough to drive confidence amidst elevated expectations,” he added. Merck’s shares on Thursday dropped after the leak but recovered and ended the day down 1 per cent. Moderna’s shares were down as much as 25 per cent in intraday trading. Analysts said it remains uncertain how the melanoma results can be applied to other cancers. Merck and Moderna are also testing their therapies in bladder, lung and other cancers. Thursday’s published results were a final phase 3 trial that has been in the works since 2023. The companies have said they are meeting the US drug regulator and expect approval next year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 995 | - | - | ||
| 5 184 | - | - | ||
| 4 816 | - | - | ||
| 500 | - | - | ||
| 819 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt